Phico Therapeutics secures up to £13.2m from CARB-X for clinical trials
The biotechnology company has obtained grant funding to advance its antibacterial therapy through Phase 1 clinical trials.
Phico Therapeutics is a biotechnology company developing engineered phage technology to create a new generation of antibiotics.
Phico Therapeutics has secured up to £13.2m in grant funding from CARB-X to advance its antibacterial therapy through Phase 1 clinical trials. The capital will support intravenous studies targeting antibiotic resistant Pseudomonas aeruginosa in ventilated associated pneumonia. The financing comprises an initial £3.8m grant followed by up to £9.4m in milestone payments.
The company uses its engineered phage platform to deliver small acid-soluble spore proteins that inactivate bacterial DNA. This approach aims to address the growing threat of drug-resistant infections without harming other cells or contributing to further antimicrobial resistance.
From the founder
"To receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance. It has been awarded at the end of a thorough due diligence process which reinforces the credibility of the company and our team – I am delighted to now look forward to progressing our lead product to clinical trials and developing a product pipeline that will advance the science of antibacterial therapy and in time, save millions of lives round the world."
Heather Fairhead
Founder and CEO at Phico Therapeutics
Investor perspective
"Phico’s innovative approach delivers the antibiotic effect of SASPs by using engineered bacteriophages to precisely target P. aeruginosa infections in the lungs,"
Erin Duffy
R&D Chief, CARB-X
Use of funds
- 01Fund research and development
- 02Continue product development
Investors
Categories
About the company
Phico Therapeutics
Developing engineered phage technology to create new antibacterial treatments.